SCHEMBL720502

SCHEMBL720502

CCCCCCCCCCCCCC(CCNCC(O)CN1CCN(CC(O)CNCCC(CCCCCCCCCCCCC)CC(O)CN)CC1)CC(O)CN

nearest known ligand 0.35

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
HTT P42858 2/20 0.35
GNAI3 P08754 1/20 0.34
GNAO1 P09471 1/20 0.34
GNAI1 P63096 1/20 0.34
KDM4E B2RXH2 1/20 0.32
OPRL1 P41146 1/20 0.32
ALDH1A1 P00352 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31
LMNA P02545 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
ANPEP P15144 1/20 0.30
ERAP2 Q6P179 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1477738 1.00 HTT (0.35) HTTGNAI3GNAO1GNAI1KDM4E
SCHEMBL717827 0.93 FFAR1 (0.33) HTTGNAI3GNAO1GNAI1
SCHEMBL717828 0.93 FFAR1 (0.33) HTTGNAI3GNAO1GNAI1
SCHEMBL716436 0.88 GNAI3 (0.35) HTTGNAI3GNAO1GNAI1KDM4E
SCHEMBL717222 0.88 GNAI3 (0.35) HTTGNAI3GNAO1GNAI1KDM4E
SCHEMBL716640 0.84 GNAI3 (0.42) HTTGNAI3GNAO1GNAI1LMNA
SCHEMBL718149 0.84 GNAI3 (0.42) HTTGNAI3GNAO1GNAI1LMNA
SCHEMBL716855 0.81 SLC6A5 (0.38) GNAI3GNAO1GNAI1
SCHEMBL716853 0.81 SLC6A5 (0.38) GNAI3GNAO1GNAI1
SCHEMBL4342012 0.80 GNAI3 (0.46) HTTGNAI3GNAO1GNAI1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4565572-A1 LIPIDS FOR NUCLEIC ACID DELIVERY Life Technologies Corporation (US) 2025-06-11 EP claimed
WO-2025034802-A2 AGENTS FOR DELIVERY OF NUCLEIC ACIDS Life Technologies Corporation (US) 2025-02-13 WO claimed
WO-2025034764-A1 LIPIDS FOR DELIVERY OF NUCLEIC ACIDS TO EUKARYOTIC CELLS Life Technologies Corporation (US) 2025-02-13 WO claimed
CN-119137109-A Lipids for nucleic acid delivery 生命技术公司 2024-12-13 CN claimed
EP-4384508-A2 LIPIDS FOR NUCLEIC ACID DELIVERY Life Technologies Corporation (US) 2024-06-19 EP claimed
WO-2024031051-A1 LIPIDS FOR NUCLEIC ACID DELIVERY Life Technologies Corporation (US) 2024-02-08 WO claimed
US-11866723-B2 Plant virus movement proteins and methods of using same Molecular Transfer Inc. (US) 2024-01-09 US claimed
EP-4175967-A2 TRINUCLEOTIDE CAP ANALOGS, PREPARATION AND USES THEREOF Life Technologies Corporation (US) 2023-05-10 EP claimed
WO-2023018990-A2 LIPIDS FOR NUCLEIC ACID DELIVERY Life Technologies Corporation (US) 2023-02-16 WO claimed
WO-2022006368-A2 TRINUCLEOTIDE CAP ANALOGS, PREPARATION AND USES THEREOF Life Technologies Corporation (US) 2022-01-06 WO claimed
EP-2912045-A2 POLYCATIONIC METHYL PHOSPHOLIPIDS FOR IMPROVED DELIVERY OF NUCLEIC ACIDS TO EUKARYOTIC CELLS Molecular Transfer, Inc. (US) 2015-09-02 EP claimed
WO-2014070687-A2 POLYCATIONIC METHYL PHOSPHOLIPIDS FOR IMPROVED DELIVERY OF NUCLEIC ACIDS TO EUKARYOTIC CELLS MOLECULAR TRANSFER, INC. (US) 2014-05-08 WO claimed
EP-2696678-A1 AGENTS FOR IMPROVED DELIVERY OF NUCLEIC ACIDS TO EUKARYOTIC CELLS Molecular Transfer, Inc. (US) 2014-02-19 EP claimed
WO-2013158127-A1 AGENTS FOR IMPROVED DELIVERY OF NUCLEIC ACIDS TO EUKARYOTIC CELLS MOLECULAR TRANSFER, INC. (US) 2013-10-24 WO claimed
EP-2015780-B1 NOVEL REAGENTS FOR TRANSFECTION OF EUKARYOTIC CELLS MOLECULAR TRANSFER INC (US) 2012-12-12 EP claimed
WO-2012142622-A1 AGENTS FOR IMPROVED DELIVERY OF NUCLEIC ACIDS TO EUKARYOTIC CELLS MOLECULAR TRANSFER, INC. (US) 2012-10-18 WO claimed
US-7915230-B2 Reagents for transfection of eukaryotic cells MOLECULAR TRANSFER, INC. (US) 2011-03-29 US claimed
US-20090023215-A1 Novel reagents for transfection of eukaryotic cells MOLECULAR TRANSFER (US) 2009-01-22 US claimed
EP-2015780-A2 NOVEL REAGENTS FOR TRANSFECTION OF EUKARYOTIC CELLS Molecular Transfer, Inc. (US) 2009-01-21 EP claimed
WO-2007130073-A2 NOVEL REAGENTS FOR TRANSFECTION OF EUKARYOTIC CELLS MOLECULAR TRANSFER, INC. (US) 2007-11-15 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11866723-B2 Plant virus movement proteins and methods of using same HDLBP, PHAX, PLTP HTT 1544/4885GNAI3 534/4885GNAO1 2667/4885
US-20090023215-A1 Novel reagents for transfection of eukaryotic cells FUS, PHAX, PICALM HTT 1075/4885GNAI3 1694/4885GNAO1 3683/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.